Immunome Inc’s recent filing unveils that its President and CEO SIEGALL CLAY B acquired Company’s shares for reported $0.63 million on Nov 21 ’24. In the deal valued at $9.54 per share,66,057 shares were bought. As a result of this transaction, SIEGALL CLAY B now holds 485,693 shares worth roughly $5.84 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, SIEGALL CLAY B bought 33,943 shares, generating $331,918 in total proceeds. Upon buying the shares at $9.78, the President and CEO now owns 519,636 shares.
Before that, Lechleider Robert bought 15,805 shares. Immunome Inc shares valued at $149,800 were divested by the Chief Medical Officer at a price of $9.48 per share. As a result of the transaction, Lechleider Robert now holds 15,805 shares, worth roughly $0.19 million.
Stephens initiated its Immunome Inc [IMNM] rating to an Overweight in a research note published on November 08, 2024; the price target was $30. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. JP Morgan began covering IMNM with “an Overweight” recommendation on April 30, 2024. Guggenheim started covering the stock on April 15, 2024. It rated IMNM as “a Buy”.
Price Performance Review of IMNM
On Tuesday, Immunome Inc [NASDAQ:IMNM] saw its stock fall -3.38% to $12.02. Over the last five days, the stock has lost -13.53%. Immunome Inc shares have risen nearly 12.34% since the year began. Nevertheless, the stocks have risen 59.42% over the past one year. While a 52-week high of $30.96 was reached on 03/07/24, a 52-week low of $7.48 was recorded on 11/20/24. SMA at 50 days reached $12.19, while 200 days put it at $15.05.
Levels Of Support And Resistance For IMNM Stock
The 24-hour chart illustrates a support level at 11.63, which if violated will result in even more drops to 11.25. On the upside, there is a resistance level at 12.47. A further resistance level may holdings at 12.93. The Relative Strength Index (RSI) on the 14-day chart is 45.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.59%. Stochastics %K at 30.64% indicates the stock is a holding.
How much short interest is there in Immunome Inc?
A steep rise in short interest was recorded in Immunome Inc stocks on 2024-11-29, dropping by -0.68 million shares to a total of 9.79 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 10.47 million shares. There was a decline of -6.98%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 29, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
